On January 30, 2019, ReveraGen joined Parent Project Muscular Dystrophy for a webinar to provide the community with an overview of the vamorolone drug development program for Duchenne, including results showing improved muscle function in completed clinical trials in 48 Duchenne boys, and a description of an ongoing clinical trial of 120 Duchenne boys that is accepting new patients at 30 sites internationally.
If you missed the live event, the recording can be found below.
Watch the Recording
About the presenters
- Eric Hoffman, PhD
Chief Executive Officer, ReveraGen
Eric Hoffman identified the dystrophin protein as the cause of Duchenne in 1987, and has been working to translate the advancing knowledge of Duchenne into therapeutic approaches since then. He started the Cooperative International Neuromuscular Research Group (CINRG) – a group that has enrolled over 1,500 children into clinical studies world wide. With non-profit foundations and academic stake holders in Duchenne he has founded three companies under venture philanthropy models, working in the Duchenne space; Reveragen.com, AgadaBio.com, TRiNDS.com. He currently splits his time CEO of ReveraGen, Professor of Pharmaceutical Sciences at State University of New York – Binghamton University, and Vice President of AGADA BioSciences.
- Suzanne Gaglianone
Patient Travel Coordinator, ReveraGen
Suzanne Gaglianone is the patient travel coordinator for ReveraGen Biopharma which involves making clinical trial travel arrangements, processing reimbursements for expenses, and patient outreach. Suzanne’s 23 year old son has Duchenne Muscular Dystrophy and she has been very active in the Duchenne community for 18 years. She lives in NJ with her husband, Mike and son, Michael.